Health Tech Forward Event 2024

Developer of custom software solutions for multiple industries. The company offers web and mobile development, IT consulting, quality assurance, and design solutions. Expertise includes front-end and back-end development, SaaS solutions, data mining & BI, AI & chatbots, and cloud solutions. Over 500 successful projects completed since 2006.

Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.

We’re the power behind the forward-thinkers, future-makers and leap-takers. We partner with innovators and investors in the UK, US, Israel, Hong Kong, Denmark and Sweden helping them ignite the bold ideas that reshape our world. We offer flexible banking solutions for start-ups, scale-ups, growth businesses, investors and those working towards IPO. Whether it’s comprehensive banking, managing cashflow, plans for buyouts or Global Funds Banking, we power ideas at every stage of their journey. From the first-time founders to the funds that back them and everything in between. Here’s to never standing still. We're proud to accelerate growth for tech and life science businesses, create meaningful connections and open a world of global opportunity for entrepreneurs and investors alike.

Hay algo que me afecta y empeora mi calidad de vida, que no es visible y que no se entiende. Somos la Fundación Visible, los que vemos la letra pequeña, los que vemos lo que esconde el asterisco. Somos los que nos comprometemos en Hacer Visible Lo Invisible para darle la importancia que se merece. Somos los proyectos que ayudan a hacer visible lo que (casi) nadie ve. #MIGRAÑA #COVIDPERSISTENTE #ENFERMEDADCRÓNICA #HEALTH #SALUD #ENDOMETRIOSIS #FATIGACRONICA #SALUDMENTAL #PACIENTE #VOZDELPACIENTE #EXPERIENCIAPACIENTE

Verdane is a specialist growth investment firm that partners with tech-enabled and sustainable European businesses. Verdane can invest as a minority or majority investor, either in single companies or through portfolios of companies, and looks to deploy inside two core growth themes; digitalisation and decarbonisation. Verdane funds hold over €6 billion in total commitments and have made over 300 investments in fast-growing businesses since 2003. Verdane’s team of over 140 investment professionals and operating experts, based out of Berlin, Munich, Copenhagen, Helsinki, London, Oslo and Stockholm, is dedicated to being the preferred growth partner to tech-enabled and sustainable businesses in Europe. Verdane is also a certified B Corporation, the most ambitious sustainability accreditation globally. The firm only backs businesses that pass its 2040 test, which indicates whether the company can thrive in a more sustainable future economy. Verdane is partly owned by the Verdane Foundation, which is focused on focused on two areas: climate change and more equitable and inclusive local communities. Further information: www.verdane.com

Amazon is the leading online retailer and marketplace for third party sellers. Retail related revenue represents approximately 75% of total, followed by Amazon Web Services' cloud computing, storage, database, and other offerings (15%), advertising services (5% to 10%), and other the remainder. International segments constitute 25% to 30% of Amazon's non-AWS sales, led by Germany, the United Kingdom, and Japan.

AXA's origins date back to Ancienne Mutuelle, which was one of the few insurers that remained after the creation of the French security system. With the threat of nationalization, a merger took place between three insurance groups: The Drouot Group, AXA (still known as Mutuelles Unies in 1982), and Presence Group. Ten years later, AXA acquired North American life insurer Equitable Holdings. This was a time of expansion as AXA also bought UAP, a French insurer. Yet, as markets crashed at the turn of the millennium, AXA decided to refocus its business and exited its stake in US investment bank Donaldson, Lufkin & Jenrette. A few years later the firm expanded again with the acquisition of Swiss insurer Winterthur. About five years ago, AXA started to reshape its portfolio to technical risks.

Karista is an early-stage venture capital firm investing in ambitious entrepreneurs. For the past 20 years, we have been backing and guiding more than 100 companies from inception to success in Health, Digital, and Technology. Because we believe that investment is not only about money but mainly about people, we provide support to our founders and entrepreneurs very early-on. We come from different backgrounds and bring various skills to help nurturing our portfolio companies on many levels. We are currently deploying three European early stage funds: our Karista’s Fourth Fund, the Paris Region Venture Fund sponsored by the Paris Region and the European Commission, and our SpaceTech fund sponsored by CNES and focusing on NewSpace.

Operator of a pharmaceutical company intended to play a vital role in advancing medical science, improving patient outcomes, and addressing global healthcare challenges. The company researches, develops, and produces drugs for oncology, cardiology, metabolic, central nervous system, psychiatric, bone, muscle, and joint diseases, enabling doctors to prescribe generic drugs with minimal side effects for low-cost treatments.

Operator of a biopharmaceutical company based in Lausanne, Switzerland. The company specializes in the development of innovative prescription drugs that target unmet medical needs, it also develops drugs for specific indications in the therapeutic areas which include immunology, metabolism, oncology, and infectious diseases, and also offers a wide range of products including Eloxatin for the treatment of colorectal cancer, decapeptide, Telstar, ipamorelin formulations for the treatment of advanced prostate cancer, female infertility, endometriosis, precocious puberty, in-vitro fertilization, uterine fibroids, Mopar, and salvacyl for the treatment of severe sexual deviations.